Zimmer Biomet Holdings, Inc. ZBH SPXR3KPHARMA
Company Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Why Investors Should Care
Trades at a P/E of 23.8, below the sector median of 25.2.
Operating margin of 18.1% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $8.23B (+7.2% YoY); net profit $705.10M.
- Trailing 12 Months Year-on-year growth — revenue +4.8%, earnings +33.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.5%, profit CAGR -0.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.50% |
| 1 Year: | 4.80% |
Compounded Profit Growth
| 5 Years: | -0.54% |
| 1 Year: | 33.80% |
Stock Price Performance
| 1 Year: | -3.99% |
| 6 Months: | +4.77% |
| 3 Months: | +12.60% |
| 1 Month: | +0.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.01 · Neutral
P/E of 23.80 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -0.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZBH Zimmer Biomet Holdings, Inc. SPXR3KPHARMA | 98.07 | 23.80 | $18.71B | 0.99% | 6.61% | 6.41% | 4.50% | -0.54% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.97B | 1.95B | 1.81B | 2.07B | 2.02B | 2.01B | 1.84B | 2.07B | 1.98B | 1.99B | 1.89B | 2.13B | 1.78B | 1.23B | 1.93B | 2.09B | 1.60B | 1.76B | 1.69B | 1.66B | 1.78B | 1.67B | 1.83B | 1.87B | 1.75B | 1.89B | 1.94B | 1.82B | - | 1.91B | 2.08B | 2.00B | 2.24B | 2.09B | 2.18B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 549.80M | 592.20M | 559.30M | 792.40M | 576.20M | - |
| Gross Profit | 1.10B | 1.14B | 1.16B | 1.19B | 1.25B | 1.31B | 1.27B | 1.16B | 1.33B | 1.29B | 1.27B | 1.16B | 1.34B | 1.28B | 1.26B | 1.21B | 1.40B | 1.15B | 653.90M | 1.21B | 1.29B | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.36B | 1.49B | 1.44B | 1.45B | 1.51B | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02B | 1.09B | 1.10B | 1.17B | 1.12B | - |
| Operating Income | - | 245.50M | 201.60M | 195.50M | - | 348.10M | 280.10M | 211.20M | - | 305.00M | 296.00M | 223.30M | - | 350.20M | 204.70M | 245.80M | - | -456.00M | -171.70M | 299.20M | - | 258.70M | 224.80M | 243.00M | 198.40M | 280.90M | 245.30M | 327.30M | 329.60M | 266.60M | 265.90M | 351.30M | 279.50M | - | 338.90M | 396.40M | 338.30M | 282.60M | 395.10M | 326.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 549.60M | 575.70M | 638.20M | 453.90M | 640.10M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 66.20M | 79.30M | 75.40M | 71.90M | 68.80M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 229.00M | 224.60M | 279.20M | 98.00M | 301.30M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.50M | 71.20M | 48.00M | -39.90M | 63.00M | - |
| Net Income | 127.00M | 108.80M | -31.30M | 158.80M | 69.60M | 299.40M | 184.20M | 98.80M | 1.23B | 174.70M | 185.00M | 162.20M | -901.10M | 246.10M | 133.70M | 431.10M | 320.70M | -508.50M | -206.60M | 242.50M | 333.70M | 198.10M | 141.90M | 145.60M | 14.20M | 153.70M | 194.00M | 232.50M | 209.60M | 162.70M | 172.40M | 242.80M | 249.10M | - | 182.00M | 152.80M | 230.90M | 139.30M | 238.10M | 198.30M |
| Diluted EPS | 0.62 | 0.54 | -0.16 | 0.78 | 0.34 | 1.47 | 0.90 | 0.48 | 6.03 | 0.85 | 0.90 | 0.79 | -4.42 | 1.20 | 0.65 | 2.08 | 1.54 | -2.46 | -1.00 | 1.16 | 1.59 | 0.94 | 0.67 | 0.69 | 0.07 | 0.73 | 0.92 | 1.11 | 1.00 | 0.77 | 0.84 | 1.18 | 1.23 | 1.20 | 0.91 | 0.77 | 1.16 | - | 1.22 | 1.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.90B | 4.12B | 4.10B | 4.22B | 4.45B | 4.47B | 4.62B | 4.67B | 6.00B | 7.67B | 7.80B | 7.93B | 7.98B | 6.13B | - | 6.94B | 7.39B | 7.68B | 8.23B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.02B | 2.08B | 2.19B | 2.49B |
| Gross Profit | 3.02B | 3.12B | 3.10B | 3.21B | 3.33B | 3.35B | 3.34B | 3.42B | - | - | - | - | - | - | - | 4.92B | 5.31B | 5.49B | 5.74B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.73B | 3.86B | 3.96B | 4.38B |
| Operating Income | 1.13B | 1.09B | 1.02B | 916.70M | 1.02B | 1.05B | 1.07B | 1.04B | 467.30M | 821.10M | 799.30M | 33.80M | 1.14B | 83.10M | - | 1.19B | 1.45B | 1.53B | 1.36B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.49B | 2.22B | 2.25B | 2.22B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 164.80M | 201.20M | 218.00M | 292.80M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 403.50M | 1.07B | 1.04B | 830.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 112.30M | 42.20M | 131.40M | 125.70M |
| Net Income | 773.20M | 848.60M | 717.40M | 596.90M | 760.80M | 755.00M | 780.40M | 720.30M | 147.00M | 305.90M | 1.81B | -379.20M | 1.13B | -138.90M | - | 231.40M | 1.02B | 903.80M | 705.10M |
| Diluted EPS | 3.26 | 3.72 | 3.32 | 2.97 | 4.03 | 4.29 | 4.54 | 4.20 | 0.77 | 1.51 | 8.90 | -1.86 | 5.47 | -0.67 | - | 1.10 | 4.88 | 4.43 | 3.55 |
| R&D Expense | - | - | - | 218.50M | 238.40M | 225.60M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Jun 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 7.24B | 7.79B | 8.00B | 8.52B | 9.01B | 9.60B | 9.66B | 27.16B | 26.68B | 26.01B | 24.13B | 24.64B | 24.42B | - | - | 21.07B | 21.50B | 21.37B | 23.09B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.43B | 4.61B | 4.67B | 5.12B |
| Cash & Equivalents | 265.70M | 463.90M | 212.60M | 691.70M | 668.90M | 768.30M | 884.30M | 1.08B | 1.08B | 1.46B | 634.10M | 524.40M | 542.80M | 617.90M | 802.10M | - | - | 375.70M | 415.80M | 525.50M | 591.90M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.15B | 2.39B | 2.24B | 2.29B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38B | 1.44B | 1.48B | 1.70B |
| Total Liabilities | - | - | 1.59B | 2.15B | 2.23B | 3.00B | 3.15B | 3.28B | 3.11B | 17.27B | 17.01B | 14.28B | 12.85B | 12.25B | 12.22B | - | - | 9.04B | 9.01B | 8.89B | 10.39B |
| Current Liabilities | - | - | 771.10M | 690.70M | 702.50M | 867.10M | 866.00M | 1.03B | 1.02B | 1.62B | 2.38B | 3.07B | 2.42B | 3.44B | 2.56B | - | - | 2.36B | 2.86B | 2.45B | 2.58B |
| Long Term Debt | - | - | 460.10M | 1.13B | 1.14B | 1.58B | 1.72B | 1.67B | 1.43B | 11.50B | 10.67B | 8.92B | 8.41B | 6.72B | 7.63B | 1.00B | - | 5.15B | 4.87B | 5.34B | 6.93B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.70B | 5.77B | 6.20B | 7.52B |
| Total Equity | 4.92B | 5.45B | 5.65B | 5.64B | 5.77B | 5.51B | 5.86B | 6.30B | 6.55B | 9.89B | 9.67B | 11.74B | 11.27B | 12.39B | 12.19B | - | - | 12.02B | 12.48B | 12.47B | 12.70B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 313.80M | 316.20M | 317.47M | 318.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.08B | 1.04B | 1.12B | 1.19B | 1.18B | 1.15B | 963.10M | - | - | 1.63B | 1.58B | 1.75B | 1.59B | 1.20B | - | 1.28B | 1.58B | 1.50B | 1.70B |
| Investing Cash Flow | -491.50M | -924.20M | -381.20M | -726.90M | -624.40M | -592.10M | -282.50M | - | - | -1.69B | -510.80M | -416.60M | -729.30M | -613.80M | - | -529.20M | -778.90M | -888.10M | -1.98B |
| Financing Cash Flow | -399.50M | -343.50M | -262.10M | -489.60M | -455.80M | -436.50M | -467.30M | - | - | -743.20M | -1.21B | -1.30B | -779.90M | -421.80M | - | -843.80M | -763.50M | -484.50M | 326.00M |
| Capital Expenditure | -192.70M | -250.00M | -105.10M | -79.20M | -113.80M | -114.70M | -100.00M | -144.90M | -167.70M | -184.70M | -156.00M | -162.70M | -207.10M | -111.90M | - | -217.60M | -394.50M | -356.80M | -276.90M |
| Free Cash Flow | 891.70M | 788.10M | 1.01B | 1.11B | 1.06B | 1.04B | 863.10M | - | - | 1.45B | 1.43B | 1.58B | 1.38B | 1.09B | - | 1.07B | 1.19B | 1.14B | 1.42B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -88.30M | 39.20M | 126.80M | 47.40M |
| Share Buybacks | 576.30M | 737.00M | 923.70M | 505.60M | 1.05B | 485.60M | 720.80M | 400.90M | 150.00M | 415.50M | - | - | - | - | - | 126.40M | 692.20M | 868.00M | 487.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 77.5% | 75.8% | 75.8% | 76.0% | 74.8% | 74.8% | 72.2% | 73.3% | - | - | - | - | - | - | - | 70.9% | 71.8% | 71.5% | 69.7% |
| Operating Margin % | 28.9% | 26.4% | 24.9% | 21.7% | 23.0% | 23.4% | 23.1% | 22.2% | 7.8% | 10.7% | 10.2% | 0.4% | 14.3% | 1.4% | - | 17.2% | 19.6% | 19.9% | 16.5% |
| Net Margin % | 19.8% | 20.6% | 17.5% | 14.1% | 17.1% | 16.9% | 16.9% | 15.4% | 2.5% | 4.0% | 23.2% | -4.8% | 14.2% | -2.3% | - | 3.3% | 13.8% | 11.8% | 8.6% |
| ROE % | 14.2% | 15.0% | 12.7% | 10.3% | 13.8% | 12.9% | 12.4% | 11.0% | 1.5% | 3.2% | 15.5% | -3.4% | 9.1% | -1.1% | - | 1.9% | 8.2% | 7.2% | 5.6% |
| ROCE % | - | 16.9% | 14.4% | 12.6% | 13.4% | 12.9% | 12.5% | 12.0% | 1.8% | 3.4% | 3.5% | 0.2% | 5.4% | 0.4% | - | 6.4% | 7.8% | 8.1% | 6.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dodge & Cox Inc. | 12.65% | 24.12M | $2.43B |
| 2 | Blackrock Inc. | 8.19% | 15.61M | $1.58B |
| 3 | Harris Associates L.P. | 6.68% | 12.74M | $1.29B |
| 4 | Vanguard Capital Management LLC | 6.62% | 12.63M | $1.27B |
| 5 | Capital International Investors | 6.39% | 12.18M | $1.23B |
| 6 | State Street Corporation | 4.65% | 8.88M | $895.80M |
| 7 | Vanguard Portfolio Management LLC | 4.43% | 8.44M | $851.86M |
| 8 | Geode Capital Management, LLC | 2.80% | 5.35M | $539.79M |
| 9 | Price (T.Rowe) Associates Inc | 2.52% | 4.80M | $484.08M |
| 10 | Invesco Ltd. | 2.09% | 3.98M | $401.61M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZBH
Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Profitable Stock to Keep an Eye On and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
1 Value Stock with Impressive Fundamentals and 2 We Question
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentia…
Zimmer Biomet (ZBH) Stock Still Looks Discounted After a 28% Five Year Slide
Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long …
Are Wall Street Analysts Bullish on Zimmer Biomet Stock?
Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.
5 Revealing Analyst Questions From Zimmer Biomet’s Q2 Earnings Call
Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1…
ZBH — Frequently Asked Questions
What is the current share price of Zimmer Biomet Holdings, Inc. (ZBH)?
As of 2026-09-07 16:24 PDT, Zimmer Biomet Holdings, Inc. (ZBH) trades at $98.07 on NYSE. Its 52-week range is $79.37 to $106.59.
What is the market capitalisation of ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) has a market capitalisation of $18.71B on NYSE.
What is the P/E ratio of ZBH?
ZBH trades at a trailing price-to-earnings (P/E) ratio of 23.80. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.47.
Does ZBH pay a dividend?
Zimmer Biomet Holdings, Inc. (ZBH) currently offers a dividend yield of 0.99%.
What is the return on equity (ROE) of ZBH?
ZBH has a return on equity (ROE) of 6.41%. Its return on capital employed (ROCE) is 6.61%.
Is ZBH a good stock to buy?
This page provides a data-driven analysis of Zimmer Biomet Holdings, Inc. (ZBH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.